Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis: a Phase 2 Non-comparative Randomised Controlled Trial

NCT03851588 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT03851588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03851588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis: a Phase 2 Non-comparative Randomised Controlled Trial
Lead sponsor
University of Cape Town
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2019
Completion date
June 28, 2022
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, tuberculosis